Price
$4.15
Decreased by -3.71%
Dollar Volume (20D)
32.18 K
ADR%
5.31
Earnings Report Date (estimate)
Nov 7, 23 (-1.08)
Market Cap.
15.51 M
Shares Float
2.44 M
Shares Outstanding
3.74 M
Beta
0.00
Price / Earnings
0.16
BPR
1.45
20D Range
3.45 4.50
50D Range
2.83 5.20
200D Range
0.47 12.00
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Aug 10, 23 0.87
Increased by +104.44%
1.43
Decreased by -39.16%
May 15, 23 -1.34
Increased by +81.39%
-1.51
Increased by +11.26%
Mar 30, 23 -0.92
Increased by +87.22%
-3.08
Increased by +70.13%
Nov 9, 22 -2.40
Increased by +73.33%
-5.50
Increased by +56.36%
Aug 11, 22 -19.60
Decreased by -104.17%
-7.50
Decreased by -161.33%
May 16, 22 -7.20
Increased by +21.74%
-7.60
Increased by +5.26%
Mar 15, 22 -7.20
Increased by +50.68%
-8.80
Increased by +18.18%
Nov 8, 21 -9.00
Increased by +22.41%
-9.05
Increased by +0.55%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 23 0.00
Decreased by N/A%
-3.26 M
Increased by +96.68%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-4.15 M
Increased by +47.72%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-110.78 M
Decreased by -1.33 K%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-4.18 M
Increased by +55.82%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-98.31 M
Decreased by -859.04%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-7.94 M
Increased by +17.89%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-7.76 M
Increased by +49.60%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-9.45 M
Increased by +23.26%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.